The doctrine of inherent anticipation, in which anticipation is found despite the absence of express disclosure in a prior art reference, has recently enjoyed a remarkable revival. In the past few years, various three-judge panels of the Court of Appeals for the Federal Circuit have significantly expanded the reach of this doctrine, increasingly affirming the inherent anticipation of claims that had been crafted specifically to extend the scope or the duration of pharmaceutical patent protection.
